[CAS NO. 1926203-09-9] Troriluzole
PRODUCTS SPECIFICATIONS [1926203-09-9]
DESCRIPTION [1926203-09-9]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 419.38 |
| Molecular Formula | C15H16F3N5O4S |
| SMILES | O=C(CN(C)C(CNC(CN)=O)=O)NC1=NC2=CC=C(OC(F)(F)F)C=C2S1 |
Summary
Troriluzole, a third-generation, tripeptide prodrug of Riluzole (HY-B0211), is an orally active glutamate modulator. Troriluzole reduces synaptic glutamate level and increases the synaptic glutamate absorption. Troriluzole has the potential for Alzheimer disease and generalized anxiety disorder (GAD) [1] [2] .
IC50 & Target
glutamate [1]
In Vitro
Troriluzole is absorbed systemically and cleaves into riluzole by aminopeptidases [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT04899921 | Dana-Farber Cancer Institute|Biohaven Pharmaceuticals, Inc. |
Melanoma|Metastatic Melanoma
|
June 30, 2021 | Phase 2 |
| NCT03299166 | Biohaven Pharmaceuticals, Inc. |
Obsessive-Compulsive Disorder
|
December 19, 2017 | Phase 2|Phase 3 |
| NCT03970447 | Global Coalition for Adaptive Research|Bayer|Kazia Therapeutics Limited|Kintara Therapeutics, Inc.|Biohaven Pharmaceuticals, Inc.|Vigeo Therapeutics, Inc. |
Glioblastoma
|
July 30, 2019 | Phase 2|Phase 3 |
| NCT03408080 | University of California, Los Angeles |
Spinocerebellar Ataxias|Spinocerebellar Ataxia Type 1|Spinocerebellar Ataxia Type 2|Spinocerebellar Ataxia 3|Spinocerebellar Ataxia Type 6|MSA-C
|
December 15, 2017 | Phase 3 |
| NCT04708834 | Biohaven Pharmaceuticals, Inc. |
Obsessive Compulsive Disorder
|
March 30, 2021 | Phase 3 |
| NCT04693351 | Biohaven Pharmaceuticals, Inc. |
Obsessive-Compulsive Disorder
|
January 29, 2021 | Phase 3 |
| NCT03605667 | Biohaven Pharmaceuticals, Inc.|Alzheimer´s Disease Cooperative Study (ADCS) |
Alzheimer Disease
|
July 31, 2018 | Phase 2 |
| NCT03701399 | Biohaven Pharmaceuticals, Inc. |
Spinocerebellar Ataxias|Spinocerebellar Ataxia Type 1|Spinocerebellar Ataxia Type 2|Spinocerebellar Ataxia Type 3|Spinocerebellar Ataxia Type 6|Spinocerebellar Ataxia Type 7|Spinocerebellar Ataxia Type 8|Spinocerebellar Ataxia Type 10
|
March 8, 2019 | Phase 3 |
| NCT04641143 | Biohaven Pharmaceuticals, Inc. |
Obsessive-Compulsive Disorder
|
December 22, 2020 | Phase 3 |
| NCT02960893 | Biohaven Pharmaceuticals, Inc. |
Spinocerebellar Ataxias|Spinocerebellar Ataxia Genotype Type 1|Spinocerebellar Ataxia Genotype Type 2|Spinocerebellar Ataxia Genotype Type 3|Spinocerebellar Ataxia Genotype Type 6|Spinocerebellar Ataxia Genotype Type 7|Spinocerebellar Ataxia Genotype Type 8|Spinocerebellar Ataxia Genotype Type 10
|
December 15, 2016 | Phase 2|Phase 3 |
| NCT03829241 | Biohaven Pharmaceuticals, Inc. |
Generalized Anxiety Disorder
|
February 19, 2019 | Phase 3 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 50 mg/mL ( 119.22 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.3845 mL | 11.9224 mL | 23.8447 mL |
| 5 mM | 0.4769 mL | 2.3845 mL | 4.7689 mL |
| 10 mM | 0.2384 mL | 1.1922 mL | 2.3845 mL |
References